Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
AssigneeMallinckrodt Inc.
InventorsKrishna Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
Life of this patent
Estimating the term…
Abstract
The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.
Claims22
A pharmaceutical composition for extended release of hydrocodone and acetaminophen, comprising:
- at least one extended release portion comprising hydrocodone or a pharmaceutically acceptable salt thereof, acetaminophen, and an extended release component;
- wherein the total amount of acetaminophen in the composition is about 325 mg to about 650 mg, and the total amount of hydrocodone or salt in the composition is about 7.5 mg to about 15 mg;
- and
- wherein composition provides an AUC0-1.27h for acetaminophen of about 3 ng·h/mL/mg to about 13 ng·h/mL/mg;
- an AUC1.27-36h for acetaminophen of about 20 ng·h/mL/mg to about 75 ng·h/mL/mg;
- an AUC0-2.4h for hydrocodone or salt of about 0.5 ng·h/mL/mg to about 5 ng·h/mL/mg;
- and AUC2.4-36h for hydrocodone or salt of about 5 ng·h/mL/mg to about 25 ng·h/mL/mg.
A therapeutically effective pharmaceutical composition for oral administration in the treatment of pain, comprising:
- at least one extended release portion comprising hydrocodone or a pharmaceutically acceptable salt thereof, acetaminophen, and an extended release component;
- wherein the total amount of acetaminophen in the composition is about 325 mg to about 650 mg, and the total amount of hydrocodone or salt in the composition is about 7.5 mg to about 15 mg;
- wherein when the composition is orally administered to a subject in need thereof, the subject attains therapeutic blood levels of both the hydrocodone and the acetaminophen within about one hour after administration of the composition and maintains analgesia for about 12 hours after administration of the composition;
- and
- wherein upon placement of the composition in an in vitro dissolution test comprising USP Paddle Method at a paddle speed of about 100 rpm in 900 ml of 0.1N HCl using a USP type II apparatus at a constant temperature of 37° C., the drug release profile substantially corresponds to the following:
- after 2 hours, no more than about 65%, by weight, of the total amount of the hydrocodone or salt is released and no more than about 80%, by weight, of the total amount of the acetaminophen is released;
- after 4 hours, from about 65% to about 85%, by weight, of the total amount of the hydrocodone or salt is released and from about 65% to about 95%, by weight, of the total amount of the acetaminophen is released;
- after 8 hours, from about 80% to about 100%, by weight, of the total amount of the hydrocodone or salt is released and from about 80% to about 100%, by weight, of the total amount of the acetaminophen is released;
- and
- after 12 hours, from about 85% to about 100%, by weight, of the total amount of the hydrocodone or salt is released and from about 85% to about 100%, by weight, of the total amount of the acetaminophen is released.
A pharmaceutical composition comprising:
- at least one immediate release portion comprising hydrocodone or a pharmaceutically acceptable salt thereof and acetaminophen and at least one extended release portion comprising an extended release component, hydrocodone or a pharmaceutically acceptable salt thereof, and acetaminophen;
- wherein the at least one immediate release portion comprises from about 20% to about 30% (w/w) of the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof, and about 40% to about 60% (w/w) of the total amount of the acetaminophen in the composition;
- wherein the total amount of acetaminophen in the composition is about 325 mg to about 650 mg, and the total amount of hydrocodone or salt in the composition is about 7.5 mg to about 15 mg;
- wherein upon oral administration, the composition maintains a therapeutic blood plasma concentration of hydrocodone of at least 5 ng/mL from about 0.75 hours to about 10 hours after administration of the composition, and wherein at least about 90% of the acetaminophen is released from the composition by about 8 hours after administration of the composition such that, by about 10 hours after administration of the composition, acetaminophen has a blood plasma concentration that is less than about 30% of acetaminophen's maximum plasma concentration.
Dependencies are inferred from the claim text.